Anatomical and Functional Outcome of Suprachoroidal Triamcinolone Injection in Patients of Refractive Diabetic Macular Oedema

Madiha  Arshad; Wajeeha  Arshad; Syed Abdullah  Mazhar; Samia  Arshad; Sohaib  Arshad

doi:10.54112/bcsrj.v6i2.1562

Authors

Madiha Arshad Department of Opthalmology, Rashid Latif Medical College/Arif Memorial Teaching Hospital Lahore, Pakistan
Wajeeha Arshad Department of Anesthesia, Hamad Medical Corporation Doha, Qatar
Syed Abdullah Mazhar Department of Opthalmology, Rashid Latif Medical College/Arif Memorial Teaching Hospital Lahore, Pakistan
Samia Arshad Department of Pharmacology, Nawaz Sharif Medical College University Of Gujrat, Pakistan
Sohaib Arshad University Sains Malaysia Health Campus Kubang Kerian Kelantan 16150, Malaysia

DOI:

https://doi.org/10.54112/bcsrj.v6i2.1562

Keywords:

Suprachoroidal triamcinolone injection, Diabetic macular edema, Best corrected visual acuity, Central macula thickness

Abstract

The most frequent cause of central vision loss in people with diabetes with diabetic retinopathy is diabetic macular edema (DME). Recently, there has been a greater interest in investigating the suprachoroidal space for medication administration to lessen the adverse effects of intravitreal steroids. Objective: "To determine mean change in macular thickness and best corrected visual acuity after suprachoroidal triamcinolone injection in patients of refractive diabetic macular oedema. Quasi-experimental study. Department of Ophthalmology, DHQ Hospital, Sahiwal, from 07-12-2021 to 07-06-2022. Methodology: Sixty eyes fulfilling selection criteria were enrolled and received an injection of triamcinolone acetonide. All patients were dilated before injection, and an indirect ophthalmoscope was placed in their hands to examine the fundus after injection. At baseline and after one month, the central macular thickened, BCVA was measured, and the change was calculated. Results: The mean age was calculated as 59.06 ± 6.02 years. Duration of diabetes was 5.36 ± 1.94 years and duration of symptoms 18.15 ± 6.57 days. Baseline BCVA was 0.28 ± 0.02, and post-treatment BCVA was 0.67 ± 0.11. Baseline central macular thickness was 469.31 ± 24.12, and post-treatment central macular thickness was 292.48 ± 8.38. The distribution of change in BCVA was 0.39 ± 0.09, and central macular thickness was 176.83 ± 15.74 (p=0.000). Our study had 75.0 %( n=45) males and 25.0% (n=15) females. Distribution of lateral side was done, 66.7 %( n=40) had left side affected and 33.3 %( n=20) had right side. Conclusion: Thus, suprachoroidal triamcinolone injection may help improve macular thickness and BCVA in patients with refractive diabetic macular oedema.

Downloads

Download data is not yet available.

References

Blinder KJ, Dugel PU, Chen S, Jumper JM, Walt JG, Hollander DA, et al. Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1). Clinical ophthalmology (Auckland, NZ). 2017;11:393-401.

Flaxman SR, Bourne RR, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. The Lancet Global Health. 2017;5(12):e1221-e34.

Wykoff CC, Hariprasad SM. DRCR protocol-T: reconciling 1-and 2-year data for managing diabetic macular edema. Ophthalmic Surgery, Lasers and Imaging Retina. 2016;47(4):308-12.

Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology. 2016;123(2):330-6.

Ciulla TA, Bracha P, Pollack J, Williams DF. Real-world outcomes of anti–vascular endothelial growth factor therapy in diabetic macular edema in the United States. Ophthalmology Retina. 2018;2(12):1179-87.

Rao P, Lum F, Wood K, Salman C, Burugapalli B, Hall R, et al. Real-world vision in age-related macular degeneration patients treated with single anti–VEGF drug type for 1 year in the IRIS registry. Ophthalmology. 2018;125(4):522-8.

Ciulla TA, Hussain RM, Pollack JS, Williams DF. Visual acuity outcomes and anti–vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49 485 eyes. Ophthalmology Retina. 2020;4(1):19-30.

Wan C-r, Kapik B, Wykoff CC, Henry CR, Barakat MR, Shah M, et al. Clinical characterization of suprachoroidal injection procedure utilizing a microinjector across three retinal disorders. Translational Vision Science & Technology. 2020;9(11):27-.

Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185-222.

He Y, Ren X-j, Hu B-j, Lam W-C, Li X-r. A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema. BMC ophthalmology. 2018;18(1):1-11.

Bressler SB, Odia I, Glassman AR, Danis RP, Grover S, Hampton GR, et al. Changes in diabetic retinopathy severity when treating diabetic macular edema with ranibizumab: DRCR.net Protocol I 5-Year Report. Retina (Philadelphia, Pa). 2018;38(10):1896-904.

He Y, Ren X-j, Hu B-j, Lam W-C, Li X-r. A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema. BMC ophthalmology. 2018;18:1-11.

Ghoraba HH, Leila M, Elgouhary SM, Elgemai EEM, Abdelfattah HM, Ghoraba HH, et al. Safety of high-dose intravitreal triamcinolone acetonide as low-cost alternative to anti-vascular endothelial growth factor agents in lower-middle-income countries. Clinical Ophthalmology. 2018:2383-91.

Villegas VM, Schwartz SG. Current and future pharmacologic therapies for diabetic retinopathy. Current pharmaceutical design. 2018;24(41):4903-10.

Bressler SB, Odia I, Glassman AR, Danis RP, Grover S, Hampton GR, et al. Changes in diabetic retinopathy severity when treating diabetic macular edema with ranibizumab: DRCR. net Protocol I 5-year report. Retina. 2018;38(10):1896-904.

Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064-77. e35.

Habot‐Wilner Z, Noronha G, Wykoff CC. Suprachoroidally injected pharmacological agents for the treatment of chorio‐retinal diseases: a targeted approach. Acta ophthalmologica. 2019;97(5):460-72.

Tayyab H, Ahmed CN, Sadiq MAA. Efficacy and safety of suprachoroidal triamcinolone acetonide in cases of resistant diabetic macular edema. Pakistan journal of medical sciences. 2020;36(2):42.

Goldstein DA, Do D, Noronha G, Kissner JM, Srivastava SK, Nguyen QD. Suprachoroidal corticosteroid administration: a novel route for local treatment of noninfectious uveitis. Translational vision science & technology. 2016;5(6):14-.

Lampen SI, Khurana RN, Noronha G, Brown DM, Wykoff CC. Suprachoroidal space alterations following delivery of triamcinolone acetonide: post-hoc analysis of the phase 1/2 HULK study of patients with diabetic macular edema. Ophthalmic Surgery, Lasers and Imaging Retina. 2018;49(9):692-7.

Wykoff CC, Khurana RN, Lampen SI, Noronha G, Brown DM, Ou WC, et al. Suprachoroidal triamcinolone acetonide for diabetic macular edema: the HULK trial. Ophthalmology Retina. 2018;2(8):874-7.

Campochiaro PA, Wykoff CC, Brown DM, Boyer DS, Barakat M, Taraborelli D, et al. Suprachoroidal triamcinolone acetonide for retinal vein occlusion: results of the tanzanite study. Ophthalmology Retina. 2018;2(4):320-8.

Behar-Cohen F. Recent advances in slow and sustained drug release for retina drug delivery. Expert Opinion on Drug Delivery. 2019;16(7):679-86.

Shatz W, Aaronson J, Yohe S, Kelley RF, Kalia YN. Strategies for modifying drug residence time and ocular bioavailability to decrease treatment frequency for back of the eye diseases. Expert opinion on drug delivery. 2019;16(1):43-57.

Biomedical C. Suprachoroidal injection of CLSTA in subjects with macular edema associated with non-infectious uveitis (PEACHTREE). NLM identifier: NCT02595398. 2017.